Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

This study has been completed.
Sponsor:
Collaborator:
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia
ClinicalTrials.gov Identifier:
NCT00335348
First received: June 7, 2006
Last updated: January 7, 2013
Last verified: August 2011

June 7, 2006
January 7, 2013
June 2006
July 2012   (final data collection date for primary outcome measure)
Overall Response Rate, defined as the best response on treatment assessed using the EBMT criteria [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Overall Response Rate, defined as the best response on treatment assessed using the EBMT criteria
Complete list of historical versions of study NCT00335348 on ClinicalTrials.gov Archive Site
  • Time To Progression, defined as the time from commencement of treatment to the date of first evidence of progressive disease. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Overall survival, defined as the time from commencement of treatment to the date of death from any cause. [ Time Frame: 2years ] [ Designated as safety issue: No ]
  • Time To Progression, defined as the time from commencement of treatment to the date of first evidence of progressive disease.
  • Overall survival, defined as the time from commencement of treatment to the date of death from any cause.
Not Provided
Not Provided
 
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse An Australian Myeloma Forum Multi-Centre Phase II Trial

This study has two main aims. The first is to assess whether Dexamethasone can increase the number of patients with who respond to Velcade.

The second aim of this study is to see whether treating patients with relapsed multiple myeloma with Velcade and Dexamethasone for a longer period of time extends the time that the myeloma is under control.

Velcade is a new drug, which is being developed for the treatment of patients with a variety of cancers. In studies to date, it has been shown to be useful in the treatment of patients with advanced multiple myeloma whose myeloma has progressed after standard drug treatment. Approximately one third of them have had a response to treatment, which has lasted for approximately 12 months. It has been associated with improvement in symptoms from the disease including improvements in blood counts, fewer blood transfusions and in a lessening of bone pain. There is some evidence that more patients respond to Velcade when it is given together with a steroid drug, Dexamethasone, which is commonly used in the treatment of Myeloma, and you may have received in the past. Only a small number of patients have been treated with Velcade and Dexamethasone from the beginning of therapy. However, many more have had Dexamethasone added later if they have failed to respond to Velcade on its own.

Velcade is approved in the USA and Europe by the Food and Drug Administration (FDA) for the treatment of patients with myeloma. However, Velcade is not approved in Australia and therefore its use in this study is considered experimental.

This study has two main aims. The first is to assess whether Dexamethasone can increase the number of patients who respond to Velcade in the controlled setting of a clinical trial. This study is specifically designed for patients who have received at least one kind of standard treatment in the past and are now in need of further therapy because their disease has relapsed. The second aim of this study is to see whether treating patients with Velcade and Dexamethasone for a longer period of time extends the time that the myeloma is under control. This is known as maintenance treatment.

Approximately 100 patients will participate around Australia.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Bortezomib
    Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
  • Drug: Dexamethasone
    Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
Experimental: Bortezomib and Dexamethasone
Interventions:
  • Drug: Bortezomib
  • Drug: Dexamethasone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
101
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient was previously diagnosed with multiple myeloma based on standard criteria and currently requires second or *third line therapy because of PD, defined as a 25% increase in M-protein, or development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium >11.5 mg/dL), or relapse from CR.*Patients will only be eligible for bortezomib as 3rd line therapy if they have received dexamethasone alone, thalidomide alone (or with corticosteroids) or revlimid alone (or with corticosteroids) as one of the 2 prior therapies.
  • Patient is of a legally consenting age, as defined by local regulations.
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  • Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Male patient agrees to use an acceptable method for contraception for the duration of the study.
  • Patient has measurable disease
  • Patient has a Karnofsky performance status ≥60%.
  • Patient has a life-expectancy >3 months.

Exclusion Criteria:

  • Primary Dexamethasone resistance
  • Prior therapy with Bortezomib
  • Prior severe allergic reactions to Bortezomib (Velcade), Boron or Mannitol
  • Neuropathy > Grade 2 with pain by NCI-CTCAE criteria
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00335348
05/69, ACTRN (pending)
Not Provided
Peter MacCallum Cancer Centre, Australia
Peter MacCallum Cancer Centre, Australia
Janssen-Cilag Ltd.
Principal Investigator: Miles Prince, MD Peter MacCallum Cancer Centre, Melbourne, Australia.
Principal Investigator: Simon Harrison, MB, BS., PhD Peter MacCallum Cancer Centre, Australia
Peter MacCallum Cancer Centre, Australia
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP